Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Understanding the Metabolic Consequences of Human Arylsulfatase A Deficiency through a Computational Systems Biology Study.
Novartis drug Gilenya® shows long-term efficacy and safety according to new data from extension of phase III head-to-head study
Breastfeeding is not related to postpartum relapses in multiple sclerosis.
Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression.
“Human Medicines” page
Avonex approval application
The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk.
Checklist for reporting and reviewing studies of experimental animal models of multiple sclerosis and related disorders.
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse.
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
Biogen Idec's TECFIDERA™ (dimethyl fumarate) approved in US as a first-line oral treatment for multiple sclerosis
UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.
T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion.
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.
Brain reserve against physical disability progression over 5 years in multiple sclerosis.
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
Genes associated with T helper 17 cell differentiation and function.
Neuroprotective effects of resident microglia following acute brain injury.
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
[Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis].
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis.
Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.

Pages